BioRestorative Therapies, Inc. cotiza a 1.75 USD y tiene una capitalización bursátil de $2M. En los últimos 12 meses ha facturado $357870 con un margen de flujo de caja libre del -3031.7%. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
BioRestorative Therapies, Inc. develops therapeutic products and medical therapies using cell and tissue protocols primarily involving adult stem cells. The company develops programs related to the treatment of disc/spine disease and metabolic disorders. Its products pipeline comprises BRTX-100, a lead cell therapy can…
| Periodo | 2026-05 | 2026-03 | 2025-11 | 2025-08 |
|---|---|---|---|---|
| Real | $-2.40 | $-6.40 | $-6.60 | $-6.00 |
| Estimado | $-6.00 | $-7.40 | $-7.60 | $-8.20 |
| Sorpresa | +60.0% | +13.5% | +13.2% | +26.8% |
| Métrica | BRTX | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | 93.4% | 57.0% | +36.3% |
| Operating Margin | -4350.1% | -38.6% | -4311.4% |
| Net Margin | -3959.4% | -33.6% | -3925.8% |
| FCF Margin | -3031.7% | -13.9% | -3017.8% |
| ROE | -3992.2% | -40.4% | -3951.8% |
| ROA | -349.1% | -32.0% | -317.1% |
| Current Ratio | 0.84 | 2.84 | -2.00 |
| Debt / Equity | — | 0.28 | — |